BioSyent to Present at LD Micro New York Investor Conference
April 01, 2024 14:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be...
BioSyent Announces Grant of Restricted Share Units
March 27, 2024 18:34 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
March 13, 2024 17:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended...
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
March 06, 2024 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent Named to 2024 TSX Venture 50
February 21, 2024 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as...
BioSyent Declares First Quarter 2024 Dividend
February 06, 2024 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
Comprise named top agency in several business, PR and marketing awards programs
December 19, 2023 06:00 ET
|
Comprise
Boulder, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Comprise® solidified its status as a leading communications agency delivering integrated public relations and digital marketing services with the...
BioSyent Announces Renewal of Normal Course Issuer Bid
December 13, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent Announces the Availability of Gelclair® in Canada
November 20, 2023 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the...
BioSyent Releases Q3 and YTD 2023 Financial Results
November 16, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended...